Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above [Phase 3]
Phase 3 study evaluating safety and immune response of an RSV vaccine when given alone or together with an influenza vaccine in adults aged …
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety and immunogenicity of STR-V003 RSV vaccine in healthy adults.
-
FDA approval · 2024-02-23FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
The FDA approved a supplemental application for Beyfortus (nirsevimab) submitted by Sanofi Vaccines US Inc. The document notes the submissio…
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older [Phase 3]
Phase 3 study of the Ad26.RSV.preF vaccine for preventing lower respiratory tract disease due to respiratory syncytial virus in adults 60 an…
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older [Phase 1, Phase 2]
Phase 1/2 study of RSV preF-based vaccine formulations in adults aged 60+ was terminated with results posted in January 2024.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-21Clinical Trial Update: Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above [Phase 3]
Phase 3 trial update evaluating immunogenicity, safety, reactogenicity, and persistence of an investigational RSV vaccine in adults 60 years…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) [Phase 1, Phase 2]
This phase 1/2 trial update reports safety, tolerability, and pharmacokinetics data for Clesrovimab (MK-1654) in infants with respiratory in…
-
CLINICAL_TRIALS trial_result · 2023-10-30Clinical Trial Update: A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects [Phase 2]
Phase 2 trial updates the assessment of EDP-938 for treating acute upper respiratory tract infection caused by Respiratory Syncytial Virus; …
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection [Phase 3]
Phase 3 trial of an Ad26.RSV.preF-based vaccine for respiratory syncytial virus infection prevention in adults aged 18–59 (including high-ri…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection [Phase 2]
Phase 2 trial to evaluate safety and antiviral activity of JNJ-53718678 in children aged 28 days to 3 years with respiratory syncytial virus…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older [Phase 3]
Phase 3 trial assessing an Ad26.RSV.preF-based RSV vaccine with and without coadministration of a high-dose seasonal influenza vaccine in ad…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating the safety and immunogenicity of Ad26.RSV.preF and RSV preF Protein vaccine combinations, with …
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old [Phase 3]
Phase 3 study assessing the immunogenicity of the Ad26.RSV.preF-based vaccine for respiratory syncytial virus in adults aged 60–75; results …
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years [Phase 3]
A Phase 3 study of Janssen's Ad26.RSV.preF-based RSV vaccine regimen in adults aged 60-75 has completed and posted its results.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above [Phase 3]
Phase 3 efficacy study of GlaxoSmithKline's investigational RSV vaccine in adults aged 60 years and older has completed. Results have been p…
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children [Phase 1]
Phase 1 study assessing the infectivity, safety, and immunogenicity of the RSV vaccine RSV 6120/∆NS2/1030s in RSV-seropositive children and …
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older [Phase 2]
Phase 2 trial of Janssen's Ad26.RSV.preF-based vaccine regimen for preventing RSV-mediated lower respiratory tract disease in adults aged 65…
-
EMA approval · 2023-07-21First RSV vaccine to protect infants up to 6 months of age and older adults
EMA announces the first RSV vaccine that can protect infants up to 6 months of age and older adults, marking a pivotal approval for RSV prev…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults [Phase 2]
Phase 2a study evaluating MVA-BN-RSV vaccination with RSV challenge in healthy adults has completed.
-
FDA approval · 2023-07-17FDA Approved: BEYFORTUS — Original Application (Sanofi Vaccines US Inc.)
FDA approved Beyfortus (nirsevimab) from an original application to prevent respiratory syncytial virus lower respiratory tract disease in h…
-
CLINICAL_TRIALS trial_result · 2023-06-23Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age [Phase 1, Phase 2]
A Phase 1/2 study evaluating the safety, tolerability and immunogenicity of the investigational RSV vaccine candidate Ad26.RSV.preF in adult…
-
EMA approval · 2023-04-26First vaccine to protect older adults from respiratory syncytial virus (RSV) infection
The European Medicines Agency announces the first vaccine approved to protect older adults from Respiratory Syncytial Virus (RSV) infection.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection [Phase 2]
A Phase 2 study of Rilematovir (JNJ-53718678) in adult outpatients with respiratory syncytial virus infection was terminated; results have b…
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) [Phase 3]
Phase 3 study of Rilematovir in infants, children, and neonates hospitalized with RSV-related respiratory infection was terminated with resu…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above [Phase 3]
A Phase 3 trial evaluated three lots of an investigational RSV vaccine in adults aged 60+, with results posted after completion.